Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Pabst Gabriel |

Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen

ALIHODŽIĆ, D; ÖZKAYA1, E; PABST, G; FOßELTEDER, J; SCONOCCHIA, T; AUINGER, L; SCHLENKE, P; SILL1, H; ZEBISCH, A; WÖLFLER, A; REINISCH, A Modeling SRSF2/TET2 mutational cooperativity in CMML development
European Hematology Association (EHA) 2024 Hybrid Congress; JUNE 13-16, 2024; Madrid, SPAIN. 2024. [Poster]

 

Dutta, S; Rezania, S; Lyssy, F; Lind, K; Vosberg, S; Thallinger, G; Zebisch, A; Wölfler, A; Pabst, G; Foßelteder, J; Reinisch, A; Sill, H; Deciphering the molecular mechanism of mesenchymal stromal cell mediated drug resistance in acute myeloid leukemia.
29th European Hematology Association Congress; JUN 13-16, 2024; Madrid, SPAIN. 2024. [Poster]

 

Lind, K; Dutta, S; Foßelteder, J; Pabst, G; Reinisch, A; Wölfler, A; Zebisch, A; Sill, H; Deciphering early steps of TP53 aberrant human leukemogenesis.
29th European Hematology Association Congress; JUN 13-16, 2024; Madrid, SPAIN. 2024. [Poster]

 

Lyssy, F; Lind, K; Zöscher, F; Zebisch, A; Wölfler, A; Pabst, G; Fosselteder, J; Reinisch, A; Sill, H; Dutta, S Modelling drug resistance conferred by mono- and bi-allelic TP53 aberrations using isogenic AML cell lines
ONCOL RES TREAT. 2023; 46: 188-189. [Poster]
Web of Science FullText

 

Pabst, G; Foßelteder, F; Schlacher, A; Auinger, L; Martinez-Krams, D; Ediriwickrema, A; Kashofer, K; Beham-Schmid, Ch; Greinix, HT; Woelfler, A; Schlenke, P; Sill, H; Zebisch, A; Majeti, R; Reinisch, A; Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells.
Blood (2021) 138 (Supplement 1): 2160.. 2022; 138: 2160-2160.-ASH Annual Meeting 2021; DEZ 11-14, 2021; Atlanta, USA. [Poster]
FullText

 

Foßelteder, J; Rosenberger, A; Pabst, G; Sill, H; Wölfler, A; Reinisch, A Calreticulin mutations transform healthy hematopoietic stem cells into myeloproliferative neoplasms.
Doctoral Day 2021 at Medical University of Graz; FEB 12, 2021; Graz, AUSTRIA. 2021. [Onlinepräsentation]

 

Foßelteder, J; Schlacher, A; Pabst, G; Amtmann, B; Schöll, W; Kashofer, K; Beham-Schmid, C; Schlenke, P; Greinix, HT; Sill, H; Woelfler, A; Zebisch, A; Reinisch, A Introduction and Genetic Correction of Calreticulin Mutations in Human Hematopoietic Stem and Progenitor Cells Sheds Light on MPN Pathogenesis
Blood. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA. Doi: 10.1182/blood-2021-147919 [Poster]
Web of Science FullText FullText_MUG

 

Pabst, G; Foßelteder, J; Schlacher, A; Auinger, L; Martinez-Krams3, D; Ediriwickrema, A; Kashofer, K; Beham-Schmid, C; Greinix, HT; Woelfler, A; Schlenke, P; Sill, H; Zebisch, A; Majeti, R; Reinisch, A Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells
Blood. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA. Doi: 10.1182/blood-2021-149591 [Poster]
Web of Science FullText FullText_MUG

 

Pabst, G; Prochazka, K; Pregartner, G; Rücker, FG; Heitzer, E; Woelfler ,A; Zebisch, A; Berghold, A; Döhner, K; Sill H. Impact of TP53 mutated subclones in acute myeloid leukemia
Blood. 2018; 132(Suppl ):-Annual Meeting of the American Society of Hematology; December 1-4, 2018; San Diego. Doi: 10.1182/blood-2018-99-110667 [Poster]
Web of Science FullText FullText_MUG

 

© Med Uni Graz Impressum